ANG Lifesciences Complete Financial Statements
In FY2026, ANG Lifesciences (ANG) reported revenue ₹24 Cr, net profit ₹-1 Cr and EPS ₹-1.07, with a net profit margin of -4.2% and ROE of -1.9%. Full financial statements from FY2020 to FY2026 (7 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see ANG share price.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
ANG Revenue, Net Profit & EBITDA — Year-on-Year Growth
ANG YoY (Mar 2025 vs Mar 2026) — revenue +33.3%, net profit +50.0%, expenses +16.7%. Analyse ANG shareholding pattern to track promoter, FII and institutional holdings.
ANG Income Statement — Revenue, EBITDA & Net Profit
ANG Lifesciences revenue ₹24 Cr, EBITDA ₹3 Cr, net profit ₹-1 Cr, EPS ₹-1.07 (2026) — net profit margin -4.2%. Examine ANG Lifesciences quarterly earnings for recent quarterly revenue, profit and EPS trends.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24 | 26 | 18 | 25 | 19 | 33 | 38 | 20 | 25 | 34 | 49 | 57 | 19 | 60 | 96 | 74 | 47 | 90 | 36 | 120 | 50 | 32 |
| Expenses | 21 | 26 | 18 | 24 | 21 | 31 | 36 | 20 | 27 | 32 | 50 | 50 | 21 | 50 | 83 | 62 | 44 | 70 | 33 | 90 | 44 | 31 |
| EBITDA | 3 | 0 | 0 | 1 | -3 | 3 | 2 | 0 | -2 | 2 | -1 | 7 | -2 | 10 | 13 | 12 | 3 | 20 | 4 | 30 | 6 | 2 |
| Operating Profit Margin % | 11.00% | 0.00% | -4.00% | 3.00% | -14.00% | 7.00% | 4.00% | -9.00% | -9.00% | 5.00% | -26.00% | 12.00% | -10.00% | 16.00% | 13.00% | 16.00% | 6.00% | 22.00% | 9.00% | 25.00% | 11.00% | 5.00% |
| Depreciation | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 2 | 1 | 0 | 1 | 2 | 0 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 3 | 4 | 2 | 1 | 1 | 2 | 1 |
| Profit Before Tax | -1 | -3 | -4 | -3 | -6 | -1 | -4 | -4 | -6 | -3 | -6 | 2 | -6 | 4 | 7 | 7 | -3 | 17 | 2 | 28 | 2 | 1 |
| Tax | 0 | 0 | -2 | -1 | -1 | 1 | 0 | -1 | -1 | 0 | -1 | 1 | 0 | 2 | 2 | 3 | -1 | 4 | 1 | 8 | 1 | 0 |
| Net Profit | -1 | -3 | -2 | -2 | -5 | -2 | -4 | -3 | -5 | -2 | -5 | 2 | -6 | 3 | 5 | 4 | -2 | 13 | 1 | 20 | 1 | 0 |
| Earnings Per Share (₹) | -1.07 | -2.24 | -1.56 | -1.52 | -3.60 | -1.53 | -2.75 | -2.35 | -3.98 | -1.74 | -3.63 | 1.41 | -4.52 | 2.20 | 5.16 | 3.99 | -1.36 | 12.41 | 2.30 | 38.66 | 1.29 | 0.42 |
ANG Balance Sheet — Assets, Liabilities & Shareholders' Equity
ANG total assets ₹209 Cr, total equity ₹53 Cr, total liabilities ₹ Cr (2026) — ROE -1.9%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| ASSETS | |||||
| Total Assets | 209 | 230 | 242 | 278 | 291 |
| Current Assets | 145 | 161 | 173 | 183 | 193 |
| Fixed Assets | 51 | 57 | 58 | 88 | 93 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 |
| Investments | 46 | 0 | 0 | 0 | 0 |
| Other Assets | 4 | 172 | 184 | 190 | 198 |
| LIABILITIES | |||||
| Total Liabilities | |||||
| Current Liabilities | 7 | 22 | 22 | 29 | 41 |
| Non-Current Liabilities | |||||
| SHAREHOLDERS' EQUITY | |||||
| Total Equity | 53 | 64 | 76 | 86 | 84 |
| Share Capital | 13 | 13 | 13 | 13 | 10 |
| Reserves & Surplus | 40 | 46 | 59 | 69 | 69 |
ANG Cash Flow Statement — Operating, Investing & Financing
ANG Lifesciences operating cash flow ₹0 Cr, investing ₹-2 Cr, financing ₹2 Cr, net cash flow ₹0 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 |
|---|---|---|---|---|
| Operating Activities | 0 | -10 | 26 | 25 |
| Investing Activities | -2 | 20 | -9 | -44 |
| Financing Activities | 2 | -10 | -17 | 20 |
| Net Cash Flow | 0 | 0 | 0 | 0 |